烧心缓解是胃食管反流病药物开发的主要未满足需求:阈值价值分析
该研究通过决策分析模型比较伏诺拉生20mg每日一次、常用质子泵抑制剂方案和不治疗在1年时间内的成本与效果。结果显示,未参保患者每年花费4443美元、保险公司花费3784美元用于治疗不充分的GERD症状;若PCABs疗效与PPIs相似,可为患者和保险公司每年节省至少3000美元,并带来0.06个QALY增益,作为覆盖选项对保险公司具有成本节省作用,阈值价格为每片8.57美元。
要点
- 烧心缓解是GERD药物开发应优先对齐的患者和医生需求。
- PCABs若疗效与PPIs相似,可节省费用并轻微改善QALY。
- 保险公司覆盖PCABs的阈值价格上限为每片8.57美元。
核心结论
- 将GERD药物开发聚焦于烧心缓解可使产业和保险公司的成本效益激励与患者及消化科医生的需求对齐。
研究设计与样本
- 决策分析模型,比较伏诺拉生20mg每日一次、常用OTC或处方PPI方案和不治疗,时间跨度1年。
- 临床应答基于近期3期多中心试验中无烧心天数的比例评估。
- 医疗资源使用来自全国观察性研究与健康对照的比较。
主要发现
- 无保险覆盖适当治疗时,患者每年平均花费4443美元,保险公司花费3784美元用于治疗不充分的GERD症状。
- 模型估计PCABs可为患者和保险公司每年节省至少3000美元成本。
- PCABs可带来每年0.06的QALY增益。
- 若未来试验证明PCABs在烧心缓解和糜烂性食管炎愈合方面与PPIs疗效相似,作为覆盖选项对保险公司具有成本节省作用,价格上限为每片8.57美元。
关键数值与推荐
- 阈值价格反映所有药品福利管理回扣和折扣后的价格。
- 临床应答评估基于3期试验中无烧心天数的比例。
临床怎么用
- 在价值医疗环境下,应优先开发能更好缓解烧心的GERD疗法。
- 保险公司可考虑以每片不超过8.57美元的价格覆盖PCABs,以实现成本节省。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Heartburn symptoms contribute to healthcare-seeking among patients with gastroesophageal reflux disease (GERD). Despite clinical guidance, management is often dictated by insurance restrictions. Several potassium-competitive acid blockers (PCABs) are under development as a new class of therapy. We performed economic analyses to align GERD drug development with the needs of gastroenterologists, insurers and patients in a value-based environment. METHODS: A decision-analytic model was constructed to compare vonoprazan 20 mg daily (an example of a PCAB), common over-the-counter or prescription proton pump inhibitor regimens, and no treatment over a 1-year time horizon. Clinical responses were evaluated based on the proportions of heartburn-free days in a recent phase 3 multicenter trial. Healthcare utilization for persistent reflux symptoms was derived from national observational studies compared with healthy control subjects. Costs and quality-adjusted life years were reported. RESULTS: Without insurance coverage for appropriate therapy, patients spend $4443 and insurers spend $3784 on average per year for inadequately treated GERD symptoms. Our model estimates that PCABs could save at least $3000 in annual costs to patients and insurers, could generate quality-adjusted life year gains (+0.06 per year), and could be cost-saving to insurers as a covered option at a price up to $8.57 per pill, if these drugs are able to demonstrate similar effectiveness to proton pump inhibitors in future trials evaluating heartburn relief and erosive esophagitis healing to regulators. Threshold prices reflect pricing after all pharmacy benefits manager rebates and discounts. DISCUSSION: We demonstrate that aiming GERD-related drug development toward heartburn relief appears critical to align cost-effective incentives for industry and insurers with those of patients and gastroenterologists.
引用
- Shah ED, Curley MA, Patel A, et al. Heartburn Relief Is the Major Unmet Need for Drug Development in Gastroesophageal Reflux Disease: Threshold Value Analysis. Clin Gastroenterol Hepatol. 2024. PMID: 38367746. doi:10.1016/j.cgh.2024.01.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。